IMMUCELL CORP (ICCC) Stock Fundamental Analysis

NASDAQ:ICCC • US4525253062

6.57 USD
+0.02 (+0.31%)
Last: Feb 27, 2026, 08:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, ICCC scores 4 out of 10 in our fundamental rating. ICCC was compared to 520 industry peers in the Biotechnology industry. ICCC has only an average score on both its financial health and profitability. ICCC is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year ICCC was profitable.
  • ICCC had a positive operating cash flow in the past year.
  • In the past 5 years ICCC always reported negative net income.
  • In multiple years ICCC reported negative operating cash flow during the last 5 years.
ICCC Yearly Net Income VS EBIT VS OCF VS FCFICCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 5.08%, ICCC belongs to the top of the industry, outperforming 91.35% of the companies in the same industry.
  • The Return On Equity of ICCC (7.80%) is better than 91.92% of its industry peers.
  • ICCC has a better Return On Invested Capital (4.41%) than 90.58% of its industry peers.
Industry RankSector Rank
ROA 5.08%
ROE 7.8%
ROIC 4.41%
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
ICCC Yearly ROA, ROE, ROICICCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5 -10 -15 -20

1.3 Margins

  • ICCC's Profit Margin of 8.37% is amongst the best of the industry. ICCC outperforms 89.81% of its industry peers.
  • ICCC's Operating Margin of 8.39% is amongst the best of the industry. ICCC outperforms 90.19% of its industry peers.
  • Looking at the Gross Margin, with a value of 40.93%, ICCC is in the better half of the industry, outperforming 74.04% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ICCC has declined.
Industry RankSector Rank
OM 8.39%
PM (TTM) 8.37%
GM 40.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
ICCC Yearly Profit, Operating, Gross MarginsICCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICCC is destroying value.
  • The number of shares outstanding for ICCC has been increased compared to 1 year ago.
  • ICCC has more shares outstanding than it did 5 years ago.
  • ICCC has a better debt/assets ratio than last year.
ICCC Yearly Shares OutstandingICCC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ICCC Yearly Total Debt VS Total AssetsICCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • ICCC has an Altman-Z score of 2.97. This is not the best score and indicates that ICCC is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of ICCC (2.97) is better than 66.73% of its industry peers.
  • The Debt to FCF ratio of ICCC is 13.27, which is on the high side as it means it would take ICCC, 13.27 years of fcf income to pay off all of its debts.
  • ICCC has a Debt to FCF ratio of 13.27. This is amongst the best in the industry. ICCC outperforms 90.38% of its industry peers.
  • ICCC has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
  • ICCC's Debt to Equity ratio of 0.27 is on the low side compared to the rest of the industry. ICCC is outperformed by 66.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 13.27
Altman-Z 2.97
ROIC/WACC0.55
WACC8.04%
ICCC Yearly LT Debt VS Equity VS FCFICCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 4.21 indicates that ICCC has no problem at all paying its short term obligations.
  • ICCC has a Current ratio of 4.21. This is comparable to the rest of the industry: ICCC outperforms 49.62% of its industry peers.
  • A Quick Ratio of 1.76 indicates that ICCC should not have too much problems paying its short term obligations.
  • ICCC has a worse Quick ratio (1.76) than 77.50% of its industry peers.
Industry RankSector Rank
Current Ratio 4.21
Quick Ratio 1.76
ICCC Yearly Current Assets VS Current LiabilitesICCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 152.00% over the past year.
  • The Revenue has grown by 16.49% in the past year. This is quite good.
  • The Revenue has been growing by 14.07% on average over the past years. This is quite good.
EPS 1Y (TTM)152%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)16.49%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%-8.32%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ICCC Yearly Revenue VS EstimatesICCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ICCC Yearly EPS VS EstimatesICCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2023 2024 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 25.27 indicates a quite expensive valuation of ICCC.
  • Compared to the rest of the industry, the Price/Earnings ratio of ICCC indicates a rather cheap valuation: ICCC is cheaper than 92.88% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.07, ICCC is valued at the same level.
Industry RankSector Rank
PE 25.27
Fwd PE N/A
ICCC Price Earnings VS Forward Price EarningsICCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ICCC is valued cheaper than 95.58% of the companies in the same industry.
  • ICCC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICCC is cheaper than 91.92% of the companies in the same industry.
Industry RankSector Rank
P/FCF 83.11
EV/EBITDA 12.95
ICCC Per share dataICCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ICCC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IMMUCELL CORP

NASDAQ:ICCC (2/27/2026, 8:10:00 PM)

6.57

+0.02 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-04
Inst Owners19.91%
Inst Owner Change-0.31%
Ins Owners26.57%
Ins Owner Change0.51%
Market Cap59.46M
Revenue(TTM)27.77M
Net Income(TTM)2.32M
Analysts82.86
Price TargetN/A
Short Float %0.2%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 25.27
Fwd PE N/A
P/S 2.14
P/FCF 83.11
P/OCF 29.88
P/B 2
P/tB 2
EV/EBITDA 12.95
EPS(TTM)0.26
EY3.96%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY1.2%
OCF(TTM)0.22
OCFY3.35%
SpS3.07
BVpS3.29
TBVpS3.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.39
Profitability
Industry RankSector Rank
ROA 5.08%
ROE 7.8%
ROCE 5.58%
ROIC 4.41%
ROICexc 4.86%
ROICexgc 4.87%
OM 8.39%
PM (TTM) 8.37%
GM 40.93%
FCFM 2.58%
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 13.27
Debt/EBITDA 1.57
Cap/Depr 47.25%
Cap/Sales 4.59%
Interest Coverage 5.01
Cash Conversion 39.59%
Profit Quality 30.79%
Current Ratio 4.21
Quick Ratio 1.76
Altman-Z 2.97
F-Score7
WACC8.04%
ROIC/WACC0.55
Cap/Depr(3y)82.27%
Cap/Depr(5y)105.22%
Cap/Sales(3y)11.34%
Cap/Sales(5y)14.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.49%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%-8.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y171.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y108.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y137.97%
OCF growth 3Y-27.78%
OCF growth 5Y9.25%

IMMUCELL CORP / ICCC FAQ

Can you provide the ChartMill fundamental rating for IMMUCELL CORP?

ChartMill assigns a fundamental rating of 4 / 10 to ICCC.


What is the valuation status of IMMUCELL CORP (ICCC) stock?

ChartMill assigns a valuation rating of 4 / 10 to IMMUCELL CORP (ICCC). This can be considered as Fairly Valued.


Can you provide the profitability details for IMMUCELL CORP?

IMMUCELL CORP (ICCC) has a profitability rating of 5 / 10.